NCT03208023 (RESIPI) is a NA clinical trial of RESIPI Management Strategy in Inotropy, sponsored by Vanderbilt University Medical Center.

Who is sponsoring NCT03208023?

NCT03208023 is sponsored by Vanderbilt University Medical Center.

What drugs are being tested in NCT03208023?

Interventions in NCT03208023: RESIPI Management Strategy, No intervention.

What condition does NCT03208023 study?

NCT03208023 studies Inotropy, Fluid Management, Cardiac Event, Perioperative Cardiac Risk, Vascular Resistance, Hemodynamic Monitoring, Hemodynamic Management, Fluid Responsiveness.

Is NCT03208023 still recruiting?

NCT03208023 is currently terminated. Last updated 17 November 2022.

Last reviewed 2022-11-17 · How we verify

NCT03208023: RESIPI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RESIPI for Reducing Perioperative Major Adverse Cardiac Events

Terminated NA Last updated 17 November 2022

What this trial tests

NA trial testing RESIPI Management Strategy in Inotropy in 155 participants. Terminated before completion.

Timeline

9 October 2017

Primary endpoint
1 November 2018

3 December 2018

Quick facts

Lead sponsor	Vanderbilt University Medical Center
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	155
Start date	9 October 2017
Primary completion	1 November 2018
Estimated completion	3 December 2018
Sites	1 location across United States

Drugs / interventions tested

RESIPI Management Strategy
No intervention

Conditions studied

Inotropy — all drugs for Inotropy →
Fluid Management — all drugs for Fluid Management →
Cardiac Event — all drugs for Cardiac Event →
Perioperative Cardiac Risk — all drugs for Perioperative Cardiac Risk →

Sponsor

Vanderbilt University Medical Center

Who can join

18 and older, any sex, with Inotropy or Fluid Management. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the effect of a novel hemodynamic management and monitoring strategy for reducing cardiac bio marker elevations and major adverse cardiac events.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Vanderbilt University Medical Center trials

Trials by the same sponsor.

NCT07005037 — Swallowing Impairments in ICU Survivors and Community-Dwelling Adults · not yet recruiting
NCT07527273 — Cognitive Enhancement in Recurrent Depression (The COG-D-R Study) · NA · not yet recruiting
NCT07295288 — Botox Injections in Non-Cranial Nerve VII Innervated Muscles for Facial Synkinesis · Phase 4 · not yet recruiting
NCT07431541 — Topical Carboxytherapy Paste Following Microneedling · Phase 1, PHASE2 · not yet recruiting
NCT07224711 — The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03208023 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vanderbilt University Medical Center
Last refreshed: 17 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03208023.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing